Clinical Trial Update: Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carbon-ion radiotherapy plus camrelizumab for locally recurrent nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Carbon ion radiotherapy (carbon ion radiotherapy)

Snippet

Sponsor: Shanghai Proton and Heavy Ion Center | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN